全文获取类型
收费全文 | 1856篇 |
免费 | 182篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 43篇 |
妇产科学 | 14篇 |
基础医学 | 328篇 |
口腔科学 | 27篇 |
临床医学 | 243篇 |
内科学 | 362篇 |
皮肤病学 | 114篇 |
神经病学 | 150篇 |
特种医学 | 58篇 |
外科学 | 225篇 |
综合类 | 16篇 |
一般理论 | 1篇 |
预防医学 | 103篇 |
眼科学 | 20篇 |
药学 | 193篇 |
中国医学 | 7篇 |
肿瘤学 | 129篇 |
出版年
2023年 | 18篇 |
2022年 | 15篇 |
2021年 | 82篇 |
2020年 | 81篇 |
2019年 | 73篇 |
2018年 | 73篇 |
2017年 | 61篇 |
2016年 | 59篇 |
2015年 | 65篇 |
2014年 | 71篇 |
2013年 | 90篇 |
2012年 | 134篇 |
2011年 | 125篇 |
2010年 | 92篇 |
2009年 | 66篇 |
2008年 | 98篇 |
2007年 | 118篇 |
2006年 | 103篇 |
2005年 | 83篇 |
2004年 | 78篇 |
2003年 | 69篇 |
2002年 | 57篇 |
2001年 | 57篇 |
2000年 | 36篇 |
1999年 | 37篇 |
1998年 | 19篇 |
1997年 | 8篇 |
1996年 | 9篇 |
1995年 | 10篇 |
1994年 | 12篇 |
1993年 | 7篇 |
1992年 | 11篇 |
1991年 | 7篇 |
1990年 | 16篇 |
1989年 | 14篇 |
1988年 | 9篇 |
1987年 | 14篇 |
1986年 | 4篇 |
1985年 | 12篇 |
1984年 | 5篇 |
1983年 | 7篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1979年 | 5篇 |
1977年 | 2篇 |
1975年 | 3篇 |
1974年 | 3篇 |
1968年 | 2篇 |
1967年 | 3篇 |
排序方式: 共有2042条查询结果,搜索用时 62 毫秒
1.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
2.
3.
4.
5.
6.
7.
Vivek Ashoka Menon Elissa Tong Dana Rose-Marie Louise Slape Tai Anh Phan Renee CF Chan 《The Australasian journal of dermatology》2020,61(1):e97-e99
Dermatitis artefacta is a self-inflicted cutaneous disease presenting as sharply delineated ulcers, usually in accessible sites such as the head and neck. IgG4-related disease (IgG4-RD) is a recently recognised immune-mediated condition causing a fibroinflammatory process, resulting in the formation of tumefactive lesions in various organs, rarely presenting primarily in the skin. We report a case of cutaneous IgG4-RD clinically presenting as dermatitis artefacta. 相似文献
8.
9.